The Canagliflozin and Kidney Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study was the first study of an SGLT-2 inhibitor to have kidney outcomes in its primary composite end point.20 The gene discussed is SLC5A2; the disease is kidney disorder.